Clinical trials: Paclitaxel, completed
Endometrial Cancer
Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
This study will evaluate the role of addition of an anti-angiogenic agent (Nintedanib/placebo) to conventional combination chemotherapy as concomitant and maintenance treatment in primary advanced or with first relapse of…
- Trial name
- NCT02730416
- Where
- 37 sites in Belgium, Denmark and 5 more
- Volunteers
- 146 people
- Sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Stage III Melanoma, Stage IV Melanoma
Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
This is a Phase II single-arm, open-label, clinical trial evaluating the efficacy and safety of pazopanib in combination with paclitaxel as first line therapy for subjects with unresectable Stage III and Stage IV melanoma.
- Conditions
- Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma
- Trial name
- NCT01107665
- Testing
- Pazopanib and Paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Irvine
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003342
- Testing
- filgrastim, carboplatin, doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
This study is testing the investigational drug, cetuximab, in combination with different chemotherapy drugs for lung cancer. The aim of the study is to determine which of the drug combinations looks most promising and should be…
- Trial name
- NCT00828841
- Testing
- Cetuximab, Paclitaxel, Carboplatin
- Where
- 84 sites in United States
- Volunteers
- 601 people
- Sponsor
- Accelerated Community Oncology Research Network
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma
- Trial name
- NCT00470366
- Testing
- pegfilgrastim, cisplatin, ifosfamide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003394
- Testing
- carboplatin, endocrine-modulating drug therapy, estramustine phosphate sodium
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Primary Peritoneal Carcinoma, Stage III Ovarian Cancer
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is most effective in treating ovarian epithelial cancer and…
- Conditions
- Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
- Trial name
- NCT00011986
- Testing
- Paclitaxel, Carboplatin, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 4,312 people
- Sponsor
- Gynecologic Oncology Group
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
The purpose of this study is: Phase A: To confirm the feasibility of paclitaxel administered by intravenous (IV) infusion weekly plus concurrent carboplatin administered by intraperitoneal (IP) injection once every 3 weeks…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- iPocc (NCT01506856)
- Testing
- Paclitaxel(intravenous) + Carboplatin(intravenous), Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
- Where
- 62 sites in United States, Hong Kong and 4 more
- Volunteers
- 655 people
- Sponsor
- Gynecologic Oncology Trial & Investigation Consortium
Metastatic Breast Cancer
Biweekly Docetaxel in Patients With Metastatic Breast Cancer.
There is clinical benefit of docetaxel administered to patients who have progressed to 3 or more lines of chemotherapy including prior exposure to paclitaxel or docetaxel; using docetaxel in metastatic stage breast cancer…
- Trial name
- NCT02041351
- Testing
- Docetaxel
- Where
- 2 sites in Mexico
- Volunteers
- 17 people
- Sponsor
- Centro Universitario contra el Cáncer
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
This phase II trial studies how well nab-paclitaxel and gemcitabine hydrochloride followed by radiation therapy before surgery work in treating patients with pancreatic cancer that can be removed by surgery.
- Trial name
- NCT02427841
- Testing
- Fluorouracil, Gemcitabine, Image Guided Radiation Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute
Unspecified Adult Solid Tumor, Protocol Specific
Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with paclitaxel and carboplatin in treating patients with advanced or refractory solid tumors.
- Trial name
- NCT00287937
- Testing
- vorinostat, paclitaxel, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
This was a 3-part study designed to explore the safety and tolerability of escalating doses of PLX3397 with weekly paclitaxel to establish a recommended Phase 2 dose (RP2D), to confirm RP2D in participants with advanced…
- Trial name
- NCT01525602
- Testing
- PLX3397, Paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 74 people
- Sponsor
- Daiichi Sankyo
Peripheral Artery Disease
Pharmacokinetic Study of Drug-coated Angioplasty Balloons in the Superficial Femoral or Popliteal Arteries:
To describe the pharmacokinetics of paclitaxel in the blood delivered from a paclitaxel coated percutaneous angioplasty balloon catheter as a result of treatment of de novo or restenotic lesion(s), occluded/stenotic or…
- Trial name
- PK (NCT01912937)
- Testing
- Angioplasty treatment with the CVI Drug-coated Balloon (DCB)
- Where
- 2 sites in New Zealand
- Volunteers
- 25 people
- Sponsor
- Spectranetics Corporation
Breast Cancer, Metastatic Breast Cancer
Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer
Single-institution phase 2 trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.
- Trial name
- NCT00403130
- Testing
- Gemcitabine, Paclitaxel, Bevacizumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- George Albert Fisher
Peripheral Arterial Disease
Singapore INfra-Genicular Angioplasty With PAclitaxel-eluting Balloon for Critical Limb Ischaemia (SINGA-PACLI) Trial
Background In patients with critical limb ischaemia (CLI), the infragenicular arteries are often involved. Without revascularisation, amputation often is imperative.
- Trial name
- SINGA-PACLI (NCT02129634)
- Testing
- CB-PTA, DEB-PTA
- Where
- 2 sites in Singapore
- Volunteers
- 136 people
- Sponsor
- Singapore General Hospital
Fallopian Tube Cancer, Ovarian Cancer
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT01402271
- Testing
- carboplatin, paclitaxel, pazopanib hydrochloride
- Where
- 9 sites in Belgium, Netherlands and 1 more
- Volunteers
- 88 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer
The purpose of this study is to compare the safety and efficacy of bi-weekly WH002(Paclitaxel Medium and Long Chain Fat Emulsion Injection,Cholesterol Bound) vs Paclitaxel both followed by bi-weekly Epirubicin and…
- Trial name
- NCT06513364
- Testing
- WH002, paclitaxel injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing Wehand-Bio Pharmaceutical Co., Ltd
Primary Breast Cancer
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
We aimed to evaluate the noninferiority of a short-term anthracycline-free chemotherapy (TC, six cycles of docetaxel and cyclophosphamide) or a short-term anthracycline-based chemotherapy (CEF-T, three cycles of…
- Trial name
- NCT04127019
- Testing
- Paclitaxel, Docetaxel, Cyclophosphamide
- Volunteers
- 2,079 people
- Sponsor
- Fudan University
Advanced or Metastatic Non-Small Cell Lung Cancer
Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study is designed to determine the clinical efficacy and toxicity of ABT-869 in combination with carboplatin and paclitaxel in the treatment of subjects with advanced or metastatic NSCLC.
- Trial name
- NCT00716534
- Testing
- ABT-869, Carboplatin, Paclitaxel
- Where
- 37 sites in United States, Australia and 4 more
- Volunteers
- 145 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Advanced Lung Cancer
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
This is an open-label phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab and with or without standard chemotherapy in patients with…
- Trial name
- NCT05664971
- Testing
- Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection, Toripalimab, Docetaxel
- Where
- China
- Volunteers
- 119 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.